Format

Send to

Choose Destination
Am J Cancer Res. 2017 Oct 1;7(10):2091-2102. eCollection 2017.

Dendritic cells based immunotherapy.

Author information

1
Department of Radiology, Feinberg School of Medicine, Northwestern UniversityChicago, IL, USA.
2
Robert H. Lurie Comprehensive Cancer CenterChicago, IL, USA.

Abstract

Dendritic cells (DCs) are the most potent antigen-presenting cells, and tumor antigen-loaded DCs (DC-vaccines) can activate tumor-specific cytotoxic T lymphocytes (CTLs) in lymphatic tissues. DC vaccination is a newly emerging and potent form of cancer immunotherapy and has clinically relevant mechanisms of action with great potential for the systemic treatment of cancers. However, clinical trials have demonstrated relatively poor therapeutic efficacy. The efficacy of DC-vaccines is strongly influenced by various techniques for the priming antigen loading onto DCs and their ability to migrate to the draining lymph nodes (LNs). Therefore, it is critical to improve DC-vaccines homing to draining LNs after administration in order to optimize DC-based therapy for individual patients. This review underlines 1) appropriate strategy to load tumor antigens onto DCs and 2) to optimize vaccine administration methods to ensure loaded DCs can migrate to LNs, in particular, Intraperitoneal (IP) injection. IP injection of DC-based vaccine may be a potential regimen for gastrointestinal tumors including hepatocellular carcinoma (HCC) and pancreatic adenocarcinoma (PDAC) since huge populations of LNs are present throughout the gastrointestinal track. Which might improve the subsequent migration to LNs.

KEYWORDS:

Dendritic cells; cancer vaccine; hepatocellular carcinoma; immunotherapy; pancreatic cancer

PMID:
29119057
PMCID:
PMC5665855

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center